GRAIL LLC Net Income Over Time
| GRAL Stock | 98.04 5.55 5.36% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out GRAIL LLC Performance and GRAIL LLC Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GRAIL LLC. If investors know GRAIL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GRAIL LLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.66) | Revenue Per Share | Quarterly Revenue Growth 0.263 | Return On Assets | Return On Equity |
The market value of GRAIL LLC is measured differently than its book value, which is the value of GRAIL that is recorded on the company's balance sheet. Investors also form their own opinion of GRAIL LLC's value that differs from its market value or its book value, called intrinsic value, which is GRAIL LLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GRAIL LLC's market value can be influenced by many factors that don't directly affect GRAIL LLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GRAIL LLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GRAIL LLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GRAIL LLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare GRAIL LLC and related stocks such as Dyne Therapeutics, Ultragenyx, and Apogee Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DYN | 264 M | (1.6 B) | 87 M | (356 M) | (67 M) | 50 M | (1.2 B) | 76 M | (4.8 M) | (13.5 M) | (58.7 M) | (149.3 M) | (165.2 M) | (235.9 M) | (317.4 M) | (365 M) | (383.3 M) |
| RARE | (6.8 M) | (6.8 M) | (16.3 M) | (35.1 M) | (59.8 M) | (145.6 M) | (245.9 M) | (302.1 M) | (197.6 M) | (402.7 M) | (186.6 M) | (454 M) | (707.4 M) | (606.6 M) | (569.2 M) | (512.3 M) | (486.7 M) |
| APGE | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (84 M) | (182.1 M) | (163.9 M) | (155.7 M) |
| XENE | (12 M) | (12 M) | (4.3 M) | 12 M | 13 M | (15.8 M) | (23 M) | (30.7 M) | (34.5 M) | (41.6 M) | (28.8 M) | (78.9 M) | (125.4 M) | (182.4 M) | (234.3 M) | (210.9 M) | (200.4 M) |
| CNTA | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (10.7 M) | (381.9 M) | (216.2 M) | (151.1 M) | (235.8 M) | (212.2 M) | (222.8 M) |
| NVST | 275.5 M | 275.5 M | 275.5 M | 275.5 M | 275.5 M | 275.5 M | 272 M | 301.1 M | 230.7 M | 217.6 M | 33.3 M | 340.5 M | 243.1 M | (100.2 M) | (1.1 B) | (1 B) | (956.4 M) |
| AAPG | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (118.5 M) | (345.3 M) | (1.5 B) | (677.6 M) | (782.4 M) | (882.9 M) | (925.6 M) | (405.4 M) | (364.9 M) | (383.1 M) |
| CELC | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (3.3 M) | (6.3 M) | (7.5 M) | (7.4 M) | (9.5 M) | (29.6 M) | (40.4 M) | (63.8 M) | (111.8 M) | (100.6 M) | (95.6 M) |
| SLNO | (6.5 M) | (6.5 M) | (6.5 M) | (3.7 M) | (13.9 M) | (15.9 M) | (12.1 M) | (15.7 M) | (13.3 M) | (30.8 M) | (24.6 M) | (30.9 M) | (24.1 M) | (39 M) | (175.8 M) | (158.3 M) | (150.4 M) |
| IDYA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (34.3 M) | (38.4 M) | (32.3 M) | (47.5 M) | (54.8 M) | (113 M) | (274.5 M) | (247 M) | (234.7 M) |
GRAIL LLC and related stocks such as Dyne Therapeutics, Ultragenyx, and Apogee Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in GRAIL LLC financial statement analysis. It represents the amount of money remaining after all of GRAIL LLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| GRAIL LLC | GRAL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1525 OBrien Drive, |
| Exchange | NASDAQ Exchange |
null 98.04
Check out GRAIL LLC Performance and GRAIL LLC Correlation. For more information on how to buy GRAIL Stock please use our How to buy in GRAIL Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
GRAIL LLC technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.